A randomised, double-blind, placebo-controlled trial of a recombinant version of human α-fetoprotein (MM-093) in patients with active rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 66, Issue 5, 2007, Pages 687-689

  Pollard, L C ^a   Murray, J ^b   Moody, M ^b   Stewart, E J ^b   Choy, E H S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; METHOTREXATE; MM 093; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE REACTION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROTEINS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 34248159533     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.059436     Document Type: Article

References (13)

1. Ostensen M, Villiger PM. Immunology of pregnancy-pregnancy as a remission inducing agent in rheumatoid arthritis. Transpl Immunol 2002;9:155-60.
2. Da Silva JA, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol 1992;11:189-94.
3. Irony-Tur-Sinai M, Grigoriadis N, Lourbopoulos A, Pinto-Maaravi F, Abramsky O, Brenner T. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp Neurol 2006;198:136-44.
4. Hooper DC, Evans RG. Anti-proliferative action of murine alpha-fetoprotein on activated T-lymphocytes. J Reprod Immunol 1989;16:83-96.
5. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci 1992;303:157-9.
6. Ogata A, Yamashita T, Koyama Y, Sakai M, Nishi S. Suppression of experimental antigen-induced arthritis in transgenic mice producing human alpha-fetoprotein. Biochem Biophys Res Commun 1995;213:362-6.
7. Brenner T, Evron S, Soffer D, Abramsky O. Treatment of experimental allergic encephalomyelitis in rabbits with alpha-fetoprotein. Isr J Med Sci 1985;21:945-9.
8. Brenner T, Zielinski A, Argov Z, Abramsky O. Prevention of experimental autoimmune myasthenia gravis in rats by fetal alpha-fetoprotein- rich fractions. Tumour Biol 1984;5:263-74.
9. Matsuura E, Kang Y, Kitakawa H, Ogata A, Kotani T, Ohtaki S, et al. Modulation of T cell function oy alpha-fetoprotein: an in vivo study on porcine thyroid peroxidase-induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein. Tumour Biol 1999;20:162-71.
10. Parker MH, Birck-Wilson E, Allard G, Masiello N, Day M, Murphy KP, et al. Purification and characterization of a recombinant version of human alpha-fetoprotein expressed in the milk of transgenic goats. Protein Expr Purif 2004;38:177-83.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Fries JF, Spitz FW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
13. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.